Therapeutic equivalence: fallacies and falsification

被引:64
作者
Garrett, AD [1 ]
机构
[1] Quintiles UK Ltd, Bracknell RG12 1HX, Berks, England
关键词
non-inferiority; drug regulation; equivalence margins; analysis populations; covariate adjustment; logistic regression;
D O I
10.1002/sim.1360
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The number of studies designed specifically to demonstrate therapeutic equivalence or alternatively non-inferiority of pharmaceutical treatments has increased dramatically in recent years, during which time awareness of the methodological issues has increased. Regulatory authorities have been quick to recognize the need for specific support and have either published or initiated the creation of relevant guidance. Common misconceptions prevail however regarding sample size estimation and the choice of the most appropriate patient population to analyse while other areas such as equivalence margin specification and covariate adjustment have been neglected. This paper challenges some of the regulatory advice and the interpretation that others have made of this guidance with the aim of stimulating further debate. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:741 / 762
页数:22
相关论文
共 44 条
[1]  
[Anonymous], 1995, STAT MED, V14, P1659
[2]  
[Anonymous], 1998, CPMPICH36396
[3]  
[Anonymous], CPMPICH36496
[4]  
[Anonymous], GUID IND BIOAV BIOEQ
[5]  
[Anonymous], 2001, GUID IND STAT APPR E
[6]  
Bristol D R, 1999, J Biopharm Stat, V9, P549, DOI 10.1081/BIP-100101195
[7]   Effect of non-random missing data mechanisms in clinical trials [J].
Choi, SC ;
Lu, IL .
STATISTICS IN MEDICINE, 1995, 14 (24) :2675-2684
[8]  
COX D, 1970, ANAL BINARY DATA, P20
[9]  
*CPMP, 1997, CPMPEWP55895
[10]  
*CPMP, 1999, CPMPEWP215899